Intraoperative Extravascular Ultrasound in the Identification of Flow-Limiting Dissections after Balloon Angioplasty in the Femoropopliteal Segment

Author:

Mwipatayi Bibombe Patrice1ORCID,Dodd James1,Hanna Joseph1ORCID,Gouëffic Yann2,Brodmann Marianne3,Guerra Mercedes4,Schmidt Andrej5,Loewe Christian6,Grözinger Gerd7,Korosoglou Grigorios8ORCID,Lichtenberg Michael9,Deloose Koen10

Affiliation:

1. Department of Vascular Surgery, Royal Perth Hospital, Perth 6000, Australia

2. Department of Vascular and Endovascular Surgery, Groupe Hospitalier Paris St. Joseph, 75014 Paris, France

3. Department of Angiology and Vascular Medicine, Medical University Graz, 8010 Graz, Austria

4. Vascular and Endovascular Surgery Department, University Hospital of Guadalajara, 19002 Madrid, Spain

5. Department of Interventional Angiology, University Hospital Leipzig, 04103 Leipzig, Germany

6. Department of Bioimaging and Image-Guided Therapy, Division of Cardiovascular and Interventional Radiology, Medical University of Vienna, 1090 Vienna, Austria

7. Abteilung für Diagnostische und Interventionelle Radiologie, University Hospital Tübingen, 72076 Tübingen, Germany

8. Cardiology and Vascular Medicine, GRN Hospital Weinheim, 69469 Weinheim, Germany

9. Vascular Center, Klinikum Arnsberg, 59821 Arnsberg, Germany

10. Vascular Surgery, AZ Sint Blasius Hospital, 9200 Dendermonde, Belgium

Abstract

Background: The BIO REACT study is designed to investigate the incremental value of Extravascular UltraSound (EVUS) added to conventional angiography, compared to conventional angiography only for the identification of Flow-Limiting Dissections (FLD) and to evaluate the safety and efficacy of the REsponse Adapted Combination Therapy (REACT) for the treatment of femoropopliteal lesions. Methods: The primary endpoints were the specificity and sensitivity of EVUS added to angiography for the detection of FLD. Secondary endpoints were primary patency of the REACT therapy within 12 months, fCD-TLR, freedom from MAE, major target limb amputations (mTLA) and survival rates within 24 months. Results: A total of 150 patients were included. EVUS added to angiography had an overall sensitivity of 29% and specificity of 93% for the detection of FLD. There was no PSVR cut-off offering a clinically acceptable trade-off between meaningful sensitivity and specificity values for the detection of FLD. At 12 months, treatment with the REACT resulted in primary patency and fCD-TLR of 81.6% and 94.3%, respectively. In addition, freedom from MAE was 94.3% at 12 months. At 24 months, the survival rate was 94.0%. No mTLA was reported up to the 24-month follow-up. Conclusions: The addition of DUS to angiography showed limited value for detecting FLD in femoropopliteal artery disease.

Funder

Biotronik AG

Publisher

MDPI AG

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3